Characterizing the Effect of Pentamidine Isethionate on the Immune System Using Mouse Splenocytes as an Experimental Model

REFERENCES

• Andersen R., Boedeker M., Ma M., Goldstein J. C. Adverse reactions associated with pentamidine isethionate in AIDS patients: Recommendations for monitoring therapy. Drug. Intell. Clin. Pharm. 1986; 20: 862–868
   PubMedGoogle Scholar
• Antoniou T., Gough K. A. Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: Case report and review of the literature. Pharmacotherapy 2005; 25: 899–903
   PubMedGoogle Scholar
• Atsmon J., Dolev E. Drug-induced hypomagnesaemia: Scope and management. Drug. Saf. 2005; 28: 763–788
   PubMed Web of Science ®Google Scholar
• Balslev U., Nielsen T. L. Adverse effects associated with intravenous pentamidine isethionate as treatment of Pneumocystis carinii pneumonia in AIDS patients. Dan. Med. Bull. 1992; 39: 366–368
   PubMedGoogle Scholar
• Corsini E., Dykstra C., Craig W. A., Tidwell R. R., Rosenthal G. J. Pneumocystis carinii induction of tumor necrosis factor-α by alveolar macrophages: Modulation by pentamidine isethionate. Immunol. Lett. 1992; 34: 303–308
   PubMedGoogle Scholar
• Dean J. H., Murray M. J. Toxic responses of the immune system. Toxicology: The Basic Science of Poisons, 4th Edition, M. O. Amdur, J. Doull, C. D. Klaasen. Pergamon Press, New York 1991; 280–333
   Google Scholar
• Delgado G., Puentes F., Moreno A., Patarroyo M. E. Flow cytometry, a useful tool for detecting the lethal effect of pentamidine on Leishmania viannia complex promastigote forms. Pharmacol. Res. 2001; 44: 281–286
   PubMedGoogle Scholar
• Descotes J. From clinical to human toxicology: Linking animal research and risk assessment in man. Toxicol. Lett. 2003; 11: 140–141
   Google Scholar
• Descotes J. Importance of immunotoxicity in safety assessment: A medical toxicologist's perspective. Toxicol. Lett. 2004; 149: 103–108
   PubMed Web of Science ®Google Scholar
• Descotes J. Immunotoxicology: Role in the safety assessment of drugs. Drug. Saf. 2005; 28: 127–136
   PubMedGoogle Scholar
• Eckhardt L. L., Rajamani S., January C. T. Protein trafficking abnormalities: A new mechanism in drug-induced long QT syndrome. Br. J. Pharmacol. 2005; 145: 3–4
   PubMed Web of Science ®Google Scholar
• Ferrante A., Secker K., Thong Y. H. Selective inhibition of the in vitro murine B lymphocyte response by Pentamidine. Int. J. Immunopharmac 1985; 7: 281–285
   PubMedGoogle Scholar
• Germolec D. R. Sensitivity and predictivity in immunotoxicity testing: Immune endpoints and disease resistance. Toxicol. Lett. 2004; 149: 109–114
   PubMed Web of Science ®Google Scholar
• Haley P. J. Species differences in the structure and function of the immune system. Toxicology. 2003; 188: 49–71
   PubMed Web of Science ®Google Scholar
• Holladay S. D., Blaylock B. L. The mouse as a model for developmental immunotoxicology. Hum. Exp. Toxicol. 2002; 21: 525–531
   PubMed Web of Science ®Google Scholar
• Lang D. S., Meier K. L., Luster M. I. Comparative effects of immunotoxic chemicals on in vitro proliferative responses of human and rodent lymphocytes. Fundam. Appl. Toxicol. 1993; 21: 535–545
   PubMedGoogle Scholar
• Launois P., Himmelrich H., Tacchini-Cottier F., Milon G., Louis J. A. New insight into the mechanisms underlying TH2 cell development and susceptibility to Leishmania major in Balb/c mice. Microbes Infect 1999; 1: 59–64
   PubMed Web of Science ®Google Scholar
• Lightburn E., Morand J. J., Meynard J. B., Kraemer P., Chaudier B., Pages F., Garnotel E., Patte J. H., Banzet S., Dampierre H., Lepage J., Morillon M., Boutin J. P., Hovette P., Chouc C. Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate. Med. Trop. 2003; 63: 35–44
   PubMedGoogle Scholar
• Lovik M. Mutant and transgenic mice in immunotoxicology: An introduction. Toxicology. 1997; 119: 65–76
   PubMedGoogle Scholar
• Olliario P. L., Guerin P. J., Gerstl S., Haaskjold A. A., Rottingen J. A., Sundar S. Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980–2004. Lancet Infect. Dis. 2005; 5: 763–774
   PubMedGoogle Scholar
• Pheng S. R., Augera C., Chakrabarti S., Massicotte E., Lamontagne L. Sensitivity to methylmercury-induced autoimmune disease in mice correlates with resistance to apoptosis of activated CD4+ lymphocytes. J. Autoimmun. 2002; 20: 147–160
   Google Scholar
• Pheng S. R., Chakrabarti S., Lamontagne L. Dose-dependent apoptosis induced by low concentrations of methylmercury in murine splenic Fas+ T-cell subsets. Toxicology 2000; 149: 115–128
   PubMedGoogle Scholar
• Poola N. R., Kalis M., Plakogiannis F. M., Taft D. R. Characterization of pentamidine excretion in the isolated perfused rat kidney. J. Antimicrob. Chemother. 2003; 52: 397–404
   PubMed Web of Science ®Google Scholar
• Rezzani R., Pompili E., Agostini C., Buffoli B., Bonomini F., Nori S., Fumagalli L., Bianchi R. Expression of non-muscle myosin heavy chain in rat heart after immunosuppressive treatment. Int. Immunopharmacol. 2006; 6: 962–967
   PubMedGoogle Scholar
• Roth D. R., Roman D., Ulrich P., Mahl A., Junker U., Perenes E. Design and evaluation of immunotoxicity studies. Exp. Toxicol. Pathol. 2006; 57: 367–371
   PubMed Web of Science ®Google Scholar
• Roy M. K., Takenaka M., Kobori M., Nakahara K., Isobe S., Tsushida T. Apoptosis, necrosis and cell proliferation-inhibition by cyclosporine A in U937 cells (a human monocytic cell line). Pharmacol. Res. 2006; 53: 293–302
   PubMed Web of Science ®Google Scholar
• Schulte A., Ruehl-Fehlert C. Regulatory aspects of immunotoxicology. Exp. Toxicol. Pathol. 2006; 57: 385–389
   PubMed Web of Science ®Google Scholar
• Snodin D. J. Regulatory immunotoxicology. Does the published evidence support mandatory non-clinical immune function screening in drug development?. Regul. Toxicol. Pharmacol. 2004; 40: 336–355
   PubMedGoogle Scholar
• Spanhaak S. The ICH S8 immunotoxicity guidance. Immune function assessment and toxicological pathology: Autonomous or synergistic methods to predict immunotoxicity?. Exp. Toxicol. Pathol. 2006; 57: 373–376
   PubMedGoogle Scholar
• Van Wauwe J., Aerts F., Van Genechten H., Blockx H., Deleersnijder W., Walter H. The inhibitory effect of pentamidine on the production of chemotactic cytokines by in vitro stimulated human blood cells. Inflamm. Res. 1996; 45: 357–363
   PubMedGoogle Scholar
• Yang Z., Peng Y., Wang S. Immunosuppressants: Pharmacokinetics, methods of monitoring and role of high performance liquid chromatography/mass spectrometry. Clin. Applied. Immunol. Rev. 2005; 5: 405–430
   Google Scholar